MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- SANOFI INDIA LIMITED (pharmaceuticals)
- SANOFI INDIA LIMITED Financial Data
Sanofi India Fact Sheet (HOCM)
Get Details: We are Bullish on These 3 Little-known Stocks
Here is the latest financial fact sheet of Sanofi India. For more details, see the Sanofi India quarterly results and Sanofi India share price and chart. For a sector overview, read our pharmaceuticals sector report.
SANOFI INDIA Price History
| % ch | % | 0.3 |
| No. of shares | m | 23.03 |
| % ch week | % | -0.6 |
| % ch 1-mth | % | -0.2 |
| % ch 12-mth | % | 3.6 |
| 52 week H/L | Rs | 8,999.0/7,322.1 |
SANOFI INDIA Financials
| No. of Mths Year Ending |
12 Dec-14 |
12 Dec-15 |
12 Dec-16 |
12 Dec-17 |
12 Dec-18 |
5-Yr Chart Click to enlarge
|
|---|
| SANOFI INDIA EQUITY SHARE DATA | |||||||
|---|---|---|---|---|---|---|---|
| High | Rs | 3,800 | 4,521 | 4,560 | 4,945 | 6,840 | |
| Low | Rs | 2,500 | 3,445 | 4,400 | 3,901 | 4,630 | |
| Sales per share (Unadj.) | Rs | 858.7 | 952.3 | 1,028.5 | 1,081.8 | 1,203.1 | |
| Earnings per share (Unadj.) | Rs | 114.5 | 139.6 | 132.1 | 141.6 | 165.3 | |
| Diluted earnings per share | Rs | 114.5 | 139.6 | 132.1 | 141.6 | 165.3 | |
| Cash flow per share (Unadj.) | Rs | 156.4 | 188.7 | 183.7 | 185.9 | 209.9 | |
| Dividends per share (Unadj.) | Rs | 45.00 | 65.00 | 68.00 | 71.00 | 84.00 | |
| Adj. dividends per share | Rs | 45.00 | 65.00 | 68.00 | 71.00 | 84.00 | |
| Dividend yield (eoy) | % | 1.4 | 1.6 | 1.5 | 1.6 | 1.5 | |
| Book value per share (Unadj.) | Rs | 645.2 | 706.5 | 753.6 | 879.9 | 963.6 | |
| Adj. book value per share | Rs | 645.2 | 706.5 | 753.6 | 879.9 | 963.6 | |
| Shares outstanding (eoy) | m | 23.03 | 23.03 | 23.03 | 23.03 | 23.03 | |
| Bonus / Rights / Conversions | - | - | - | - | - | ||
| Price / Sales ratio | x | 3.7 | 4.2 | 4.4 | 4.1 | 4.8 | |
| Avg P/E ratio | x | 27.5 | 28.5 | 33.9 | 31.2 | 34.7 | |
| P/CF ratio (eoy) | x | 20.1 | 21.1 | 24.4 | 23.8 | 27.3 | |
| Price / Book Value ratio | x | 4.9 | 5.6 | 5.9 | 5.0 | 6.0 | |
| Dividend payout | % | 39.3 | 46.6 | 51.5 | 50.2 | 50.8 | |
| Avg Mkt Cap | Rs m | 72,545 | 91,724 | 103,174 | 101,862 | 132,078 | |
| No. of employees | `000 | 3.4 | 3.7 | 3.6 | 3.2 | 3.3 | |
| Total wages/salary | Rs m | 2,882 | 3,333 | 3,553 | 3,685 | 4,068 | |
| Avg. sales/employee | Rs Th | 5,735.2 | 5,987.0 | 6,537.7 | 7,691.9 | 8,393.8 | |
| Avg. wages/employee | Rs Th | 836.0 | 909.9 | 980.7 | 1,137.7 | 1,232.4 | |
| Avg. net profit/employee | Rs Th | 764.5 | 877.7 | 839.6 | 1,006.5 | 1,153.0 | |
| SANOFI INDIA INCOME DATA | |||||||
|---|---|---|---|---|---|---|---|
| Net Sales | Rs m | 19,775 | 21,930 | 23,686 | 24,914 | 27,708 | |
| Other income | Rs m | 643 | 514 | 664 | 807 | 897 | |
| Total revenues | Rs m | 20,418 | 22,444 | 24,350 | 25,721 | 28,605 | |
| Gross profit | Rs m | 3,389 | 4,591 | 5,351 | 5,372 | 6,235 | |
| Depreciation | Rs m | 966 | 1,130 | 1,188 | 1,022 | 1,027 | |
| Interest | Rs m | 5 | 4 | 23 | 11 | 7 | |
| Profit before tax | Rs m | 3,061 | 3,970 | 4,804 | 5,146 | 6,098 | |
| Minority Interest | Rs m | 0 | 0 | 0 | 0 | 0 | |
| Prior Period Items | Rs m | 0 | 0 | 0 | 0 | 0 | |
| Extraordinary Inc (Exp) | Rs m | 666 | 839 | 0 | 0 | 0 | |
| Tax | Rs m | 1,090 | 1,594 | 1,762 | 1,886 | 2,292 | |
| Profit after tax | Rs m | 2,636 | 3,215 | 3,042 | 3,260 | 3,806 | |
| Gross profit margin | % | 17.1 | 20.9 | 22.6 | 21.6 | 22.5 | |
| Effective tax rate | % | 35.6 | 40.1 | 36.7 | 36.6 | 37.6 | |
| Net profit margin | % | 13.3 | 14.7 | 12.8 | 13.1 | 13.7 | |
| SANOFI INDIA BALANCE SHEET DATA | |||||||
|---|---|---|---|---|---|---|---|
| Current assets | Rs m | 12,628 | 12,437 | 15,753 | 14,438 | 15,922 | |
| Current liabilities | Rs m | 6,558 | 4,945 | 5,021 | 6,017 | 6,235 | |
| Net working cap to sales | % | 30.7 | 34.2 | 45.3 | 33.8 | 35.0 | |
| Current ratio | x | 1.9 | 2.5 | 3.1 | 2.4 | 2.6 | |
| Inventory Days | Days | 88 | 80 | 76 | 61 | 64 | |
| Debtors Days | Days | 21 | 24 | 22 | 29 | 21 | |
| Net fixed assets | Rs m | 8,582 | 8,771 | 8,098 | 7,991 | 7,539 | |
| Share capital | Rs m | 230 | 230 | 230 | 230 | 230 | |
| "Free" reserves | Rs m | 14,559 | 16,004 | 17,088 | 20,034 | 21,962 | |
| Net worth | Rs m | 14,858 | 16,272 | 17,356 | 20,264 | 22,192 | |
| Long term debt | Rs m | 0 | 0 | 0 | 0 | 0 | |
| Total assets | Rs m | 22,276 | 24,114 | 25,412 | 27,777 | 29,839 | |
| Interest coverage | x | 638.6 | 993.5 | 209.9 | 468.8 | 872.1 | |
| Debt to equity ratio | x | 0 | 0 | 0 | 0 | 0 | |
| Sales to assets ratio | x | 0.9 | 0.9 | 0.9 | 0.9 | 0.9 | |
| Return on assets | % | 11.9 | 13.3 | 12.1 | 11.8 | 12.8 | |
| Return on equity | % | 17.7 | 19.8 | 17.5 | 16.1 | 17.2 | |
| Return on capital | % | 25.1 | 29.6 | 27.8 | 25.4 | 27.5 | |
| Exports to sales | % | 24.2 | 24.2 | 24.5 | 0 | 0 | |
| Imports to sales | % | 36.9 | 26.1 | 28.0 | 0 | 0 | |
| Exports (fob) | Rs m | 4,788 | 5,312 | 5,801 | 0 | 0 | |
| Imports (cif) | Rs m | 7,298 | 5,720 | 6,627 | 0 | 0 | |
| Fx inflow | Rs m | 5,495 | 6,680 | 7,145 | 6,306 | 7,587 | |
| Fx outflow | Rs m | 8,045 | 6,587 | 6,846 | 5,257 | 7,145 | |
| Net fx | Rs m | -2,550 | 93 | 299 | 1,049 | 442 | |
| SANOFI INDIA CASH FLOW | |||||||
|---|---|---|---|---|---|---|---|
| From Operations | Rs m | 2,650 | 2,132 | 3,221 | 4,351 | 3,739 | |
| From Investments | Rs m | 613 | 359 | -1,550 | -787 | -731 | |
| From Financial Activity | Rs m | -1,217 | -1,470 | -1,802 | -1,884 | -1,972 | |
| Net Cashflow | Rs m | 2,046 | 1,021 | -131 | 1,680 | 1,036 | |
Share Holding
|
Company Information
|
|||||||||||||||||||||||||||||||||||||||||
| CHM: Vijay Mallya | COMP SEC: K. Subramani | YEAR OF INC: 1956 | BSE CODE: 500674 | FV (Rs): 10 | DIV YIELD (%): 1.1 |
Read: SANOFI INDIA 2017-18 Annual Report Analysis
More Pharmaceuticals Company Fact Sheets: NATCO PHARMA IPCA LABS DR. REDDYS LAB PFIZER INDRAPRASTHA MEDICAL
Compare SANOFI INDIA With: NATCO PHARMA IPCA LABS DR. REDDYS LAB PFIZER INDRAPRASTHA MEDICAL
Compare SANOFI INDIA With: ACTAVIS (US) MYLAN (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
Today's Market
5 Reasons Why Sensex Zoomed 613 Points Today(Closing)
Indian share markets extended gains as the session progressed and ended on a strong note.
Views on news
SANOFI INDIA Announces Quarterly Results (2QFY21); Net Profit Up 5.0% (Quarterly Result Update)
Oct 29, 2020 | Updated on Oct 29, 2020For the quarter ended September 2020, SANOFI INDIA has posted a net profit of Rs 1 bn (up 5.0% YoY). Sales on the other hand came in at Rs 7 bn (down 11.9% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.
SANOFI INDIA Announces Quarterly Results (1QFY21); Net Profit Up 39.9% (Quarterly Result Update)
Aug 26, 2020 | Updated on Aug 26, 2020For the quarter ended June 2020, SANOFI INDIA has posted a net profit of Rs 1 bn (up 39.9% YoY). Sales on the other hand came in at Rs 7 bn (down 5.0% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.
Gland Pharma Q4 results: Net profit rises 34%; Share Price Hits New 52-Week High (Views On News)
May 18, 2021The new vaccine business is expected to accelerate the company's long-term strategy of entering into the biosimilar space.
Cipla's Q4 Update: Net Profit Surges 68%; Company to Pay Rs 5 Dividend (Views On News)
May 17, 2021Here's a rundown on the latest quarterly results of Cipla.
Dr Reddy's Lab Shares Fall As Earnings Miss Estimates. What Next? (Views On News)
May 14, 2021The company's board recommended a final dividend of Rs 25 for financial year 2020-21.
More Views on NewsMost Popular
Is Intraday Trading For You? (Fast Profits Daily)
May 13, 2021Do you think you have what it takes to be an intraday trader? Find out in this video.
My Secret to Find Breakthrough Stocks (Fast Profits Daily)
May 7, 2021I've used this trading technique for many years with great success. I'm sharing it with you today.
Are the Stock Markets Deaf to Covid Agony? (Profit Hunter)
May 6, 2021Why are markets discounting the economic impact of Covid?
The Key to Profit from India's EV Revolution (Profit Hunter)
May 7, 2021Stocks you must consider investing in before buying your first electric vehicle.
MoreOUR TOP 5 IDEAS
- Revealing at 5pm Today: The Great Indian Wealth Project
- Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
- Covid-19 Proof Multibagger Stocks - Download this FREE Report Now
- Free Report: The Secret to Increasing Your Trading Profits Daily!
- No Guessing, No Hunches, and No Missed Trends Ever! Join Us on YouTube Now.
TRACK SANOFI INDIA
- Track your investment in SANOFI INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON SANOFI INDIA
SANOFI INDIA - MYLAN COMPARISON
COMPARE SANOFI INDIA WITH
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
- Basics of Value Investing
- Benjamin Graham
- How to Invest in Gold
- How to Invest in Silver
- Best Stocks to Buy Today
- Warren Buffett - The Value Investor
- The Best Small-cap Stocks to Buy
- The Best Bluechip Stocks to Buy
- Your Ultimate Guide to Penny Stock Investing
- 10 Rules for Successful Long-Term Investing
- How to Invest in the Share Market
- Momentum Moves
FOLLOW
APP
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.